DE60128916D1 - Neues, physiologisch aktives peptid und dessen verwendung - Google Patents
Neues, physiologisch aktives peptid und dessen verwendungInfo
- Publication number
- DE60128916D1 DE60128916D1 DE60128916T DE60128916T DE60128916D1 DE 60128916 D1 DE60128916 D1 DE 60128916D1 DE 60128916 T DE60128916 T DE 60128916T DE 60128916 T DE60128916 T DE 60128916T DE 60128916 D1 DE60128916 D1 DE 60128916D1
- Authority
- DE
- Germany
- Prior art keywords
- peptide
- compound
- salt
- screening
- new
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 238000012216 screening Methods 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000217442 | 2000-07-18 | ||
| JP2000217442 | 2000-07-18 | ||
| JP2001026779 | 2001-02-02 | ||
| JP2001026779 | 2001-02-02 | ||
| PCT/JP2001/006162 WO2002006483A1 (fr) | 2000-07-18 | 2001-07-17 | Nouveau peptide actif sur le plan physiologique et utilisation associee |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60128916D1 true DE60128916D1 (de) | 2007-07-26 |
| DE60128916T2 DE60128916T2 (de) | 2007-09-20 |
Family
ID=26596235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60128916T Expired - Lifetime DE60128916T2 (de) | 2000-07-18 | 2001-07-17 | Neues, physiologisch aktives peptid und dessen verwendung |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7045299B2 (de) |
| EP (1) | EP1302542B1 (de) |
| AT (1) | ATE364698T1 (de) |
| AU (1) | AU2001272735A1 (de) |
| DE (1) | DE60128916T2 (de) |
| WO (1) | WO2002006483A1 (de) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223727B2 (en) * | 1998-04-09 | 2007-05-29 | Serono Genetics Institute S.A. | GSSP4 polynucleotides and polypeptides and uses thereof |
| AU6728000A (en) * | 1999-08-27 | 2001-03-26 | Takeda Chemical Industries Ltd. | Novel g protein-coupled receptor protein and dna thereof |
| US6485938B1 (en) * | 1999-11-16 | 2002-11-26 | Zymogenetics, Inc. | Nucleic acid molecules that encodes human Zven1 |
| WO2002036625A2 (en) | 2000-11-03 | 2002-05-10 | The Regents Of The University Of California | Prokineticin polypeptides, related compositions and methods |
| AU2002367629A1 (en) * | 2001-02-05 | 2003-10-08 | Bristol-Myers Squibb Company | A novel human g-protein coupled receptor, hgprbmy14, related to the orphan gpcr, gpr73 |
| AU2003244347A1 (en) * | 2002-02-04 | 2003-09-02 | Takeda Chemical Industries, Ltd. | Angiogenesis inhibitors |
| EP1485107A1 (de) * | 2002-02-11 | 2004-12-15 | Vertex Pharmaceuticals Incorporated | Phospholipide als caspase-hemmer-prodrugs |
| CA2500587A1 (en) | 2002-10-04 | 2004-04-22 | The Regents Of The University Of California | Screening and therapeutic methods relating to neurogenesis |
| WO2004031367A2 (en) * | 2002-10-07 | 2004-04-15 | Zymogenetics, Inc. | Uses of human zven proteins and polynucleotides |
| EP1589033A4 (de) * | 2003-01-22 | 2006-04-12 | Takeda Pharmaceutical | Antikörper und dessen verwendung |
| CA2622575A1 (en) * | 2005-09-13 | 2007-03-22 | Zymogenetics, Inc. | Prok2 antagonists and methods of use |
| JP2007121271A (ja) * | 2005-09-30 | 2007-05-17 | National Institute Of Advanced Industrial & Technology | ８−ヒドロキシ−２’−デオキシグアノシンの測定方法及び測定のための装置 |
| CA2678194A1 (en) | 2007-02-09 | 2008-08-14 | Tokyo Metropolitan Organization For Medical Research | Anti-human brak (cxcl14) monoclonal antibody and use thereof |
| JP5504513B2 (ja) * | 2008-02-19 | 2014-05-28 | 株式会社タニタ | カラム充填剤、これを用いたカラムおよび分離方法 |
| MX2015005546A (es) | 2012-11-13 | 2015-08-05 | Regeneron Pharma | Anticuerpos anti-receptor de procineticinas (prokr) y usos de los mismos. |
| US9942187B2 (en) | 2014-03-10 | 2018-04-10 | Harry Leonard Perper | Alert for messages “stuck” in a message queue within a messaging application |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| EP3215191B1 (de) | 2014-11-05 | 2024-08-14 | Voyager Therapeutics, Inc. | Aadc-polynukleotide zur behandlung von morbus parkinson |
| CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
| EP3448987A4 (de) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | Zusammensetzungen zur behandlung einer erkrankung |
| EP3448874A4 (de) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Zusammensetzungen zur behandlung einer erkrankung |
| IL297576B2 (en) | 2016-05-18 | 2024-02-01 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
| US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| EP3831281B1 (de) | 2016-08-30 | 2026-02-25 | The Regents of The University of California | Vorrichtungen und systeme für biomedizinische zielführung und verabreichung |
| RU2662944C1 (ru) * | 2017-02-17 | 2018-07-31 | Общество с ограниченной ответственностью "Группа развития "АПЕКС" | Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена prok 1 и/или уменьшением количества белка прокинетицина 1 на основе генно-терапевтических субстанций с геном prok 1, способ получения и использования |
| MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
| EP3618839A4 (de) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | Zusammensetzungen und verfahren zur behandlung von amyotropher lateralsklerose (als) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| US11512327B2 (en) | 2017-08-03 | 2022-11-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of AAV |
| MX2020003042A (es) | 2017-09-29 | 2020-11-18 | Voyager Therapeutics Inc | Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa. |
| TW202413649A (zh) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| EP3762500A1 (de) | 2018-03-06 | 2021-01-13 | Voyager Therapeutics, Inc. | Aus insektenzelle hergestellte teilweise selbstkomplementäre aav-genome |
| CN112424359A (zh) | 2018-05-15 | 2021-02-26 | 沃雅戈治疗公司 | 用于治疗帕金森氏病的组合物和方法 |
| US20210207167A1 (en) | 2018-05-16 | 2021-07-08 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
| WO2019222444A2 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Directed evolution |
| US20210254103A1 (en) | 2018-07-02 | 2021-08-19 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
| WO2020023612A1 (en) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
| CA3125770A1 (en) | 2019-01-18 | 2020-07-23 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
| US20220243225A1 (en) | 2019-04-29 | 2022-08-04 | Voyager Therapeutics, Inc. | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS |
| EP4010465A1 (de) | 2019-08-09 | 2022-06-15 | Voyager Therapeutics, Inc. | Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren |
| EP4022070A1 (de) | 2019-08-26 | 2022-07-06 | Voyager Therapeutics, Inc. | Kontrollierte expression viraler proteine |
| EP4192514A1 (de) | 2020-08-06 | 2023-06-14 | Voyager Therapeutics, Inc. | Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren |
| WO2022187473A2 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
| CN120543373B (zh) * | 2025-07-29 | 2025-10-03 | 中国海洋大学 | 基于递归双流Mamba的海温补全方法及系统 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5891720A (en) | 1997-04-17 | 1999-04-06 | Millennium Pharmaceuticals, Inc. | Isolated DNA encoding a novel human G-protein coupled receptor |
| JP2001512013A (ja) | 1997-08-01 | 2001-08-21 | ジェンセット | 前立腺に発現される分泌タンパク質の５’ｅｓｔ |
| IL139686A0 (en) * | 1998-06-02 | 2002-02-10 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| AU2172300A (en) | 1998-12-10 | 2000-06-26 | Synaptic Pharmaceutical Corporation | Dna encoding a mammalian receptor (fb41a) and uses thereof |
| JP2002539773A (ja) | 1999-03-01 | 2002-11-26 | ミレニウム ファーマシューティカルズ，インコーポレーテッド | 分泌タンパク質およびそれらをコードする核酸 |
| AU2600800A (en) * | 1999-03-08 | 2000-09-28 | Genentech Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| JP2002543840A (ja) | 1999-05-19 | 2002-12-24 | インサイト・ゲノミックス・インコーポレイテッド | 細胞外シグナル伝達分子 |
| AU3246100A (en) | 1999-06-02 | 2000-12-28 | Genentech Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| JP2004522402A (ja) * | 1999-06-02 | 2004-07-29 | ジェネンテック・インコーポレーテッド | 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸 |
| AU6728000A (en) * | 1999-08-27 | 2001-03-26 | Takeda Chemical Industries Ltd. | Novel g protein-coupled receptor protein and dna thereof |
| AU1608201A (en) * | 1999-11-16 | 2001-05-30 | Zymogenetics Inc. | Human zven proteins |
-
2001
- 2001-07-17 EP EP01951893A patent/EP1302542B1/de not_active Expired - Lifetime
- 2001-07-17 DE DE60128916T patent/DE60128916T2/de not_active Expired - Lifetime
- 2001-07-17 US US10/333,192 patent/US7045299B2/en not_active Expired - Fee Related
- 2001-07-17 AU AU2001272735A patent/AU2001272735A1/en not_active Abandoned
- 2001-07-17 AT AT01951893T patent/ATE364698T1/de not_active IP Right Cessation
- 2001-07-17 WO PCT/JP2001/006162 patent/WO2002006483A1/ja not_active Ceased
-
2005
- 2005-12-15 US US11/304,129 patent/US7419956B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20040077535A1 (en) | 2004-04-22 |
| ATE364698T1 (de) | 2007-07-15 |
| US7045299B2 (en) | 2006-05-16 |
| WO2002006483A1 (fr) | 2002-01-24 |
| US7419956B2 (en) | 2008-09-02 |
| DE60128916T2 (de) | 2007-09-20 |
| EP1302542A1 (de) | 2003-04-16 |
| US20060088915A1 (en) | 2006-04-27 |
| AU2001272735A1 (en) | 2002-01-30 |
| EP1302542B1 (de) | 2007-06-13 |
| EP1302542A4 (de) | 2005-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE364698T1 (de) | Neues, physiologisch aktives peptid und dessen verwendung | |
| PL2157192T3 (pl) | Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin) | |
| DE60311272D1 (de) | Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten | |
| ATE484494T1 (de) | Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen | |
| WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
| ATE316077T1 (de) | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten | |
| EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
| DE60233433D1 (de) | PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN | |
| EP1978362A3 (de) | Cross-Beta-Struktur mit Amyloid-bindenden Proteinen und Verfahren für den Nachweis einer Cross-Beta-Struktur, zur Modulation der Fibrillenbildung von Cross-Beta-Strukturen und Cross-Beta-Struktur-vermittelter Toxizität | |
| ATE209684T1 (de) | Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung | |
| EA200401319A1 (ru) | Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине | |
| ATE526023T1 (de) | Pyridoxamin zur verwendung in der behandlung von diabetischer nephropathie bei typ ii diabetes | |
| DK1234025T3 (da) | Humane enzymer fra metalloproteasefamilien | |
| DE60216457D1 (de) | Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten | |
| EA200501711A1 (ru) | Семейство секретируемых белков | |
| DE50212280D1 (de) | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren | |
| DE60107888D1 (de) | Beta-Interferon zur Behandlung von Immunerkrankungen | |
| NO20034269L (no) | Anvendelse av forbindelser med den biologiske aktivitet til vaskoaktivt intestinalt peptid for behandlingen av kronisk obstruktiv pulmonalsykdom | |
| DE60311822D1 (de) | Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen | |
| WO2002062944A2 (en) | Novel physiologically active peptide and use thereof | |
| ATE422500T1 (de) | Neue chelidonin-derivate, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von pharmazeutischen wirkstoffen | |
| DE50308032D1 (de) | Isoliertes fluoreszierendes protein aus clytia gregaria cgfp, sowie dessen verwendung | |
| IL169256A (en) | Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it | |
| ATE423780T1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| ATE374260T1 (de) | Asthma-assoziiertes gen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |